Skip to search formSkip to main contentSkip to account menu

IN 1130

Known as: IN-1130, IN1130 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Transforming growth factor-β1 receptor inhibition preserves glomerulotubular integrity during ureteral obstruction in adults but worsens injury in neonatal mice.
Unilateral ureteral obstruction (UUO), a widely used model of chronic kidney disease and congenital obstructive uropathy, causes… 
2012
2012
Activin Receptor-Like Kinase 5 Inhibitor Attenuates Fibrosis in Fibroblasts Derived from Peyronie's Plaque
Purpose Transforming growth factor-β1 (TGF-β1) is the key fibrogenic cytokine associated with Peyronie's disease (PD). The aim of… 
2009
2009
AIMECS 09--Seventh AFMC International Medicinal Chemistry Congress. 23-27 August 2009, Cairns, Queensland, Australia.
  • Danny Chan
  • IDrugs : the investigational drugs journal
  • 2009
  • Corpus ID: 28576940
The Seventh Asian Federation for Medicinal Chemistry (AFMC) International Medicinal Chemistry Congress (AIMECS) held in Cairns… 
2009
2009
Fibrin으로 유도된 페이로니병 동물모델에서 transforming growth factor-β 제1형 수용체억제제인 IN-1130의 효과
Purpose: Transforming growth factor-β1 (TGF-β1) has been known to be involved in the pathogenesis of Peyronie’s disease (PD). In… 
2009
2009
EFFECT OF ALK5 INHIBITOR, IN-1130 ON THE EXPRESSION OF SNON AND SKI : TGF-β NEGATIVE REGULATORS
2009
2009
Effect of IN-1130, a Novel Transforming Growth Factor-beta Type I Receptor Kinase (ALK5) Inhibitor, on a Rat Model of Peyronie's Disease Induced by Repeated Intratunical Injections of Fibrin.
2009
2009
INHIBITION OF EPITHELIAL-MESENCHYMAL TRANSITION (EMT) BY IN-1130, A SMALL MOLECULAR INHIBITOR OF TRANSFORMING GROWTH FACTOR-β TYPE I RECEPTOR KINASE
2008
2008
Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
The authors investigated the pharmacokinetics and metabolism of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl… 
2008
2008
Distribution and Metabolism of New ALK-5 inhibitor, IN-1130 and Toxicity of Novel Paclitaxel Solubilizer, Aceporol 330
2006
2006
IN-1130, a Novel Anti-metastatic Agent in MMTV/c-Neu Mice, was Tested for the Toxicity and Metabolism in vitro and in vivo
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)